Indeed, studies suggest that Dot1l itself can serve as a prognostic biomarker for ovarian cancer and gastric cancer (Zhang et al., 2017; Song et al., 2020), and pharmacological inhibition of its activities with EPZ-5676 has a beneficial effect in patients with mixed lineage leukemia (Stein et al., 2018). This evidence concerns the gene DOT1L and ovarian cancer.